New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2013
05:55 EDTARTC, ARTC, ARTC, ARTC, ARTC, MDT, MDT, MDT, MDT, MDT, MGLN, MGLN, MGLN, MGLN, MGLN, MAKO, MAKO, MAKO, MAKO, MAKO, KYO, KYO, KYO, KYO, KYO, ECL, ECL, ECL, ECL, ECL, COV, COV, COV, COV, COV, CYH, CYH, CYH, CYH, CYH, CFN, CFN, CFN, CFN, CFN, BMTI, BMTI, BMTI, BMTI, BMTI, BAX, BAX, BAX, BAX, BAX, AXGN, AXGN, AXGN, AXGN, AXGN, AUXL, AUXL, AUXL, AUXL, AUXL, OSIR, OSIR, OSIR, OSIR, OSIRAmerican Academy of Orthopaedic Surgeons to host annual meeting
AAOS 2013 Annual Meeting is being held in Chicago on March 19-23.
News For ARTC;AUXL;AXGN;BAX;BMTI;CFN;CYH;COV;ECL;KYO;MAKO;MGLN;MDT;OSIR From The Last 14 Days
Check below for free stories on ARTC;AUXL;AXGN;BAX;BMTI;CFN;CYH;COV;ECL;KYO;MAKO;MGLN;MDT;OSIR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 14, 2014
08:16 EDTAUXLAuxilium management to meet with UBS
Subscribe for More Information
08:05 EDTCOVCovidien announces FDA 510(k) clearance for Kangaroo feeding tube
Subscribe for More Information
07:39 EDTMDTEdwards Lifesciences upgraded to Buy from Fair Value at CRT Capital
Subscribe for More Information
07:02 EDTCYHCommunity Health upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information
06:22 EDTMDTMedtronic downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
06:21 EDTMDTEdwards Lifesciences upgraded to Neutral from Underweight at JPMorgan
Subscribe for More Information
April 13, 2014
15:10 EDTMDTMedtronic says CoreValve ruling has no impact outside U.S.
Subscribe for More Information
April 12, 2014
19:50 EDTMDTEdwards says court limits sale of Medtronic CoreValve system in U.S.
Edwards Lifesciences (EW) announced that the U.S. District Court for the District of Delaware granted a preliminary injunction limiting the sale of Medtronic's (MDT) CoreValve system in the United States. The court ordered the injunction to go into effect in seven business days. The hearing related to a federal jury decision in 2010 that CoreValve willfully infringes Edwards' U.S. Andersen transcatheter aortic valve replacement patent. At the conclusion of the hearing, Chief Judge Gregory Sleet ordered Edwards and Medtronic to confer on what instances the CoreValve device could continue to be used in the treatment of U.S. patients at centers currently trained on CoreValve. There is a large body of evidence demonstrating the safety and performance of the Edwards SAPIEN valves, and the company remains committed to ensuring patients have appropriate access to transcatheter therapy. This case was initiated by Edwards in 2008. On April 1, 2010, a federal jury found Medtronic willfully infringed Edwards' U.S. Andersen patent and awarded damages. In Nov. 2012, the U.S. Court of Appeals for the Federal Circuit affirmed the jury decision; in Oct. 2013, the U.S. Supreme Court declined to hear Medtronic's appeal. The patent involved in this suit is part of the Andersen family of patents. The U.S. Andersen patent was issued in 1995. A petition has been filed with the U.S. Patent and Trademark Office to extend this patent into early 2016. In a separate case, a federal jury in January found that Medtronic CoreValve had willfully infringed Edwards' U.S. Cribier transcatheter heart valve patent, and awarded damages to Edwards in that trial.
April 11, 2014
11:42 EDTCOVCovidien liability from recall appears limited, says Brean Capital
Subscribe for More Information
08:10 EDTCOVCovidien implements voluntary recall of devices
Subscribe for More Information
07:06 EDTAUXLVIVUS announces avanafil clinical data presentation
Subscribe for More Information
April 10, 2014
19:10 EDTMDTMedtronic confirms FDA approval for expanded indications
Subscribe for More Information
16:32 EDTMDTMedtronic gets FDA approval for revised labeling application
The U.S. FDA approved an application from Medtronic for revised labeling for two cardiac resynchronization pacemakers and eight cardiac resynchronization defibrillators, expanding the indication for use to patients with atrioventricular block and less severe heart failure. The FDA previously approved these devices for patients with more severe heart failure as evaluated by their physician using specific criteria. The new approved use includes patients with less severe heart failure, but who are already indicated to receive RV pacing. With the new indication, these patients will be eligible to receive a device that will pace both sides of their heart instead of just the right. Reference Link
April 9, 2014
08:24 EDTARTCPiper Jaffray's medtech analysts hold an analyst/industry conference call
The MedTech Analyst Team focuses on Piper Jaffray's covered universe from the perspective of Technical Analyst Johnson ahead of 1Q14 earnings results on an Analyst/Industry conference call to be held on April 11 at 10 am.
08:03 EDTOSIROsiris announces receipt of $15M cash payment for Prochymal
Subscribe for More Information
April 8, 2014
09:23 EDTMGLNLeerink views final rates as favorable for MA plans
Subscribe for More Information
07:26 EDTMDT, COVElsevier Business Intelligence to hold a conference
Subscribe for More Information
07:22 EDTBAXCaSA-ISPE to hold a conference
21st Annual Lilfe Sciences Technology Conference is being held in Raleigh, North Carolina on April 8.
April 7, 2014
07:58 EDTMDTMedtronic data positive for C.R. Bard, says Barclays
Barclays said Medtronic's (MDT) better than expected drug coated balloon data could have a positive class effect that benefits C.R. Bard (BCR). The firm reiterates its Overweight rating C.R. Bard and raised its price target to $165 from $160. Note that BofA/Merrill downgraded C.R. Bard to Neutral from Buy following the Medtronic's news.
07:38 EDTMDTMedtronic data should lead to approval of drug-coated balloon, says Wells Fargo
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use